| HS Code | 849793 |
| Product Name | Spiramycin Base Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable |
| Cas Number | 8025-81-8 |
| Molecular Formula | C43H74N2O14 (Spiramycin I, principal component) |
| Molecular Weight | 843.1 g/mol (anhydrous base, principal component) |
| Appearance | White to slightly yellow crystalline or amorphous powder |
| Solubility | Slightly soluble in water; soluble in methanol, ethanol, and acetone; freely soluble in dilute acids |
| Melting Point | 134-137°C (decomposition) |
| Storage Conditions | Store in tightly closed containers, protected from light, moisture, and heat, in a cool dry place |
| Route Of Administration | Oral and Injectable |
| Dosage Form Compatibility | Suitable for manufacturing tablets, capsules, granules, and oral/injectable formulations |
As an accredited Spiramycin base Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Spiramycin base API is packed in sealed double polyethylene-lined drums, 25 kg net per drum, with nitrogen purging for stability. |
| Container Loading (20′ FCL) | 20' FCL container loaded with Spiramycin base Pharma Grade API in sealed, palletized drums for oral and injectable pharmaceutical use. |
| Shipping | Spiramycin base Pharma Grade API is shipped in sealed, double-layered polyethylene-lined aluminum bags inside sturdy fiber drums. Packaging meets GMP standards, with tamper-evident seals and clear labeling. Transport is via validated, temperature-controlled logistics to protect purity. Shipments comply with international pharmaceutical, customs, and safety regulations for oral and injectable API materials. |
| Storage | Store Spiramycin base Pharma Grade API in a tightly sealed, original container, protected from light and moisture. Keep in a cool, dry, well-ventilated area at controlled room temperature (15–25°C), or refrigerated if required on the certificate of analysis. Avoid exposure to heat, direct sunlight, and humidity. Do not use if container damaged. |
| Shelf Life | Shelf life: 36 months when stored as directed in original sealed containers, protected from light, moisture, and heat. |
Tablet cores containing spiramycin base at label strengths of 1.5 MIU and 3.0 MIU are manufactured by high-shear wet granulation rather than direct compression because the ungranulated API frequently arrives with a poured bulk density of 0.28–0.35 g/mL, a tapped bulk density of 0.38–0.48 g/mL, and a Carr index above 28, which causes punch fill variation beyond 5.0% RSD on rotary presses operating above 35 strokes/min. At an assay-corrected potency of 4,500 IU/mg, a 3.0 MIU tablet requires 666.7 mg spiramycin base, corresponding to 64.0–70.0% w/w of a 1,000 mg core. The API is first charged through a cone mill fitted with a 500 µm screen to disintegrate needle-like agglomerates. A pre-mix comprising spiramycin base 64.0–70.0% w/w, microcrystalline cellulose 12.0–15.0% w/w, pregelatinized maize starch 8.0–10.0% w/w, crospovidone 3.0–4.0% w/w, and colloidal anhydrous silica 1.0–1.5% w/w is loaded into a top-drive high-shear granulator with a working volume of 600 L. Purified water is added at 12–16% w/w over 3–5 min while impeller tip speed is maintained at 5.0–6.5 m/s and chopper speed at 1,500 rpm; granulation endpoint is accepted when impeller power draw increases 20–25% over the dry-mix baseline. The wet mass is milled through a 5.0 mm screen and dried in a fluid bed dryer with inlet air at 65–70°C, product temperature controlled at 38–43°C, and final loss on drying of 1.5–2.5% w/w. The dried granulate is milled through a 0.8–1.0 mm screen and lubricated with magnesium stearate 0.75–1.0% w/w. Compression is performed on a 55-station rotary tablet press fitted with 19 mm × 9.5 mm elongated punches, with precompression force 8–12 kN and main compression force 18–25 kN; tablets are accepted when hardness is 80–120 N, friability is ≤1.0% after 100 rotations, and disintegration is ≤15 min per Ph. Eur. 2.9.1. Aqueous film coating with a hydroxypropyl methylcellulose-based system is applied to a 2.5–3.5% w/w weight gain at bed temperature 40–45°C to reduce the bitter taste of the free base. Release and stability testing follows ICH Q1A(R2), ICH Q3D, Ph. Eur. 2.2.29 liquid chromatography for assay and related substances, Ph. Eur. 2.9.3 or USP <711> for dissolution, Ph. Eur. 2.9.40 or USP <905> for content uniformity, and Ph. Eur. 5.1.4 for non-sterile microbial quality. Terminal dosage forms are film-coated oral tablets at 1.5 MIU and 3.0 MIU, supplied in PVC/aluminium and aluminium/aluminium blisters.
Hard gelatin capsule filling of spiramycin base at 1.5 MIU and 3.0 MIU doses on dosator-type machines operating above 60,000 capsules/h is constrained by the API’s needle-shaped particle habit and electrostatic charge accumulation at relative humidity below 35% RH. When untreated spiramycin base is loaded into a dosator capsule filler, fill weight relative standard deviation commonly exceeds 4.5%, which exceeds the capability required for content uniformity acceptance under USP <905>. Dry granulation by roller compaction is therefore used to convert the API into free-flowing granules with a bulk density of 0.58–0.65 g/mL and a Hausner ratio below 1.25. For a 1.5 MIU hard gelatin capsule, API addition is 60.0–65.0% w/w of the final dry blend; for a 3.0 MIU capsule, API addition rises to 65.0–72.0% w/w because of the higher dose mass. A representative capsule fill formulation is spiramycin base 64.0% w/w, lactose monohydrate 21.0% w/w, pregelatinized starch 8.0% w/w, crospovidone 3.0% w/w, colloidal silicon dioxide 1.0% w/w, and sodium stearyl fumarate 1.5% w/w. Roller compaction is performed on a roller compactor with 250 mm diameter rolls, roll gap 2.0–2.4 mm, hydraulic pressure 70–90 bar, and roll speed 4–8 rpm; the compact is milled through a 0.8 mm screen at 1,500 rpm. If the roller band surface temperature exceeds 50°C, sticking and potency loss are observed on production lots, so water-jacketed rolls are required. The granulate is filled into size 0 or 00 hard gelatin capsules, with moisture content of the final blend controlled at ≤2.5% w/w to prevent shell brittleness and dissolution delay. In-process sampling follows 21 CFR 211.110; release testing includes content uniformity per USP <905>, dissolution per USP <711>, microbial enumeration per Ph. Eur. 2.6.12 and 2.6.13, and elemental impurities per ICH Q3D. Capsule filling yields hard gelatin capsules at 1.5 MIU and 3.0 MIU, packaged in cold-form aluminium blisters when moisture protection is required.
| Powder property | Pre-compacted spiramycin base | Roller-compacted granulate | Reference method |
|---|---|---|---|
| Bulk density | 0.28–0.35 g/mL | 0.58–0.65 g/mL | Ph. Eur. 2.9.34 |
| Hausner ratio | 1.30–1.40 | 1.18–1.22 | Ph. Eur. 2.9.34 |
| Carr index | 28–35% | 15–18% | Ph. Eur. 2.9.34 |
| Dosator fill weight RSD | 4.5–6.0% | 1.8–2.5% | In-process balance data |
Spiramycin base granulated for extemporaneous oral suspension is formulated as a dry syrup that reconstitutes to 250 mg spiramycin base per 5 mL in purified water, requiring an API addition ratio of 8.0–15.0% w/w of the dry powder mass depending on fill weight and dosing volume. Because spiramycin base is poorly wettable and intensely bitter, the formulation is granulated with mannitol and sucrose as substrate, povidone K30 2.0–3.0% w/w as binder, sodium carboxymethylcellulose 0.5–1.0% w/w as suspending agent, and a methacrylic acid–ethyl acrylate copolymer 3.0–5.0% w/w for pH-dependent taste masking. Top-spray fluid bed granulation is performed in a Glatt GPCG 120 or equivalent, with inlet air at 55–65°C, product temperature maintained at 32–38°C, spray rate 80–120 g/min, and atomizing pressure 1.5–2.0 bar; final loss on drying is controlled at <1.5% w/w. The dried granulate is milled through a 0.8 mm screen, blended with flavoring agents in a tumble blender, and filled into sachets or bottles under relative humidity not exceeding 35% RH with desiccant. The reconstituted suspension is targeted to a viscosity of 100–300 mPa·s at 25°C using a Brookfield viscometer spindle 2 at 50 rpm. Compliance includes uniformity of mass per Ph. Eur. 2.9.5, water activity <0.60, non-sterile microbial limits per Ph. Eur. 5.1.4, assay per Ph. Eur. 2.2.29, ICH Q3D, and stability per ICH Q1A(R2). The resulting finished dosage forms are granules for oral suspension at 250 mg/5 mL and 750,000 IU/5 mL, supplied as single-dose sachets of 15 g or 30 g fill weight.
Because spiramycin base has an aqueous solubility below 1.0 mg/mL at 25°C and pH 6.5–7.5, direct reconstitution in water-for-injection produces visible precipitation. Injectable processing of the free base is therefore limited to non-aqueous or co-solvent systems, or to lyophilized cakes prepared after stoichiometric acid addition. A lyophilized cake is made by dissolving sterile spiramycin base at 50–80 mg/mL in an ethanol/water or tert-butanol/water co-solvent system containing a pharmaceutically acceptable acid in a 1.0:1.0 molar ratio to the base, followed by filtration through a 0.22 µm PVDF membrane into 10 mL Type I glass vials. API addition in the final freeze-dried cake then represents 55–75% w/w, with mannitol 10–25% w/w as bulking agent and buffer salts 2–5% w/w; published data for this exact free-base lyophilization configuration remain limited, and most commercial injectable products use spiramycin adipate, so additional compatibility studies under ICH Q8 are required before scale-up. The lyophilization cycle freezes the solution to -45°C at 0.5°C/min, followed by primary drying at shelf temperatures of -25°C to -15°C and chamber pressure 100–200 µbar for 24–36 h; secondary drying proceeds at +30°C and 50 µbar until residual moisture is <2.0% w/w. Cake collapse is observed when product temperature exceeds -20°C during primary drying. Capping is conducted under EU GMP Annex 1 Grade A/B and ISO 14644-1:2015 Class 5. Compliance includes USP <788> for particulate matter, USP <85> or Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 2.6.1 for sterility, and FDA 21 CFR 211.113 for sterilization process validation. Final injectable dosage forms are sterile lyophilized powders for injection at 1.5 MIU and 3.0 MIU after reconstitution.
Fixed-dose combination tablets containing spiramycin base 1.5 MIU and metronidazole 250 mg are commercially manufactured as mono-layered or bilayered tablets; mono-layered processing requires separate granulation because the two actives exhibit opposed flow and moisture-sensitivity characteristics. Spiramycin base is granulated with microcrystalline cellulose and pregelatinized starch, while metronidazole is granulated with maize starch and povidone K30. The addition ratio of spiramycin base in the final core mixture is 45.0–50.0% w/w, metronidazole 12.0–14.0% w/w, maize starch 10.0–15.0% w/w, microcrystalline cellulose 10.0–12.0% w/w, povidone K30 2.0–3.0% w/w, crospovidone 3.0–5.0% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.75–1.0% w/w. Each granulate is dried to loss on drying 1.5–2.0% w/w, milled through a 0.8 mm screen, and blended in a 1,000 L bin blender at 6–8 rpm for 15–20 min; if blend moisture exceeds 2.5%, metronidazole can cause discoloration of the spiramycin-containing granulate. Compression is performed on a rotary press with 19 mm × 9 mm punches, hardness 80–120 N, and friability ≤1.0%. A film coating weight gain of 2.5–3.5% w/w is applied. Release testing includes assay by Ph. Eur. 2.2.29, content uniformity by USP <905> with acceptance value below 15.0, dissolution by USP <711> in 0.1 M HCl at 37°C, elemental impurities per ICH Q3D, and stability per ICH Q1A(R2). Final dose forms are fixed-dose combination film-coated tablets packaged in aluminium/aluminium blisters.
Competitive Spiramycin base Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Spiramycin base, CAS 8025-81-8, is a fermentation-derived macrolide antibiotic complex obtained from selected strains of Streptomyces ambofaciens. The principal component, spiramycin I, has the empirical formula C43H74N2O14 and a nominal molecular mass of 843.06 g/mol. The active pharmaceutical ingredient is a controlled mixture of spiramycin I, spiramycin II, and spiramycin III; the ratio is confirmed by HPLC against the current European Pharmacopoeia reference standard. The base is a white to yellowish-white powder, practically insoluble in water and soluble in organic solvents such as methanol and dichloromethane. It is supplied in unmicronized, micronized, and sterile-micronized grades for tablet, capsule, granule, and injectable formulation. Release testing for pharmaceutical-grade material includes liquid chromatography per Ph. Eur. 2.2.29, loss on drying per Ph. Eur. 2.2.32, sulphated ash per Ph. Eur. 2.4.14, residual solvents per ICH Q3C and Ph. Eur. 2.4.24, and elemental impurities per ICH Q3D and Ph. Eur. 2.4.20. The injectable grade requires sterility by Ph. Eur. 2.6.1 and bacterial endotoxin control by Ph. Eur. 2.6.14. Particle-size distribution is determined by laser diffraction per Ph. Eur. 2.9.31 or USP <429>.
For oral solid-dosage manufacturing, the unmicronized grade is typically reserved for capsule filling or wet granulation where reduced surface area is acceptable. The micronized grade is selected when content uniformity in low-dose tablets is controlled by blending with lactose monohydrate, microcrystalline cellulose, and disintegrant. Tablet and capsule release tests include uniformity of content per Ph. Eur. 2.9.6 or USP <905>, dissolution using a product-specific method validated according to USP <711>, and related substances by compendial HPLC. The injectable grade is not interchangeable with oral material; it is manufactured under more stringent control of particulate matter, bioburden, and endotoxin because the free base is practically insoluble and is generally applied as a sterile micronized suspension or as a solubilized form after salt conversion.
| Attribute | Test method | Oral unmicronized | Oral micronized | Injectable sterile micronized |
|---|---|---|---|---|
| Description | Visual examination | White to yellowish-white powder | White to yellowish-white fine powder | White to off-white sterile powder |
| Identification | Ph. Eur. 2.2.29 HPLC profile | Corresponds to spiramycin I, II, III reference standard | Corresponds to reference standard | Corresponds to reference standard |
| Related substances | Ph. Eur. 2.2.29 | Individual and total limits per current monograph | Individual and total limits per current monograph | Individual and total limits per current monograph |
| Loss on drying | Ph. Eur. 2.2.32 | Certificate of analysis limit | Certificate of analysis limit | Certificate of analysis limit |
| Sulphated ash | Ph. Eur. 2.4.14 | Certificate of analysis limit | Certificate of analysis limit | Certificate of analysis limit |
| Residual solvents | Ph. Eur. 2.4.24 / ICH Q3C | Class 1, Class 2, Class 3 limits | Class 1, Class 2, Class 3 limits | Class 1, Class 2, Class 3 limits |
| Elemental impurities | Ph. Eur. 2.4.20 / ICH Q3D | Oral PDE limits | Oral PDE limits | Parenteral PDE limits |
| Microbial enumeration | Ph. Eur. 2.6.12, 2.6.13 | Non-sterile limits | Non-sterile limits | Not applicable after sterility |
| Sterility | Ph. Eur. 2.6.1 | Not required | Not required | Must conform |
| Bacterial endotoxins | Ph. Eur. 2.6.14 | Not required unless specified | Not required unless specified | Below calculated injectable limit |
| Particle-size distribution | Ph. Eur. 2.9.31 / USP <429> | Coarse end for capsule fill | Reduced D50 for content uniformity | Sterile micronized for suspension |
For oral solid dosage forms, the unmicronized grade is selected when particle-size reduction is not required to achieve the target dissolution profile. The micronized grade is selected when low-dose tablet content uniformity requires a smaller median particle size and larger specific surface area. The final choice is not governed by particle size alone; bulk density, tapped density, and powder flow must also be reviewed because they determine the fill consistency of the tablet press and capsule filler. A flow aid such as colloidal silicon dioxide may be added at a concentration determined by flow studies; overuse can reduce blend potency and contribute to segregation of the mixture.
In high-shear wet granulation, spiramycin base is premixed with lactose monohydrate, microcrystalline cellulose, and partially pregelatinized starch in a production-scale granulator. The impeller speed, chopper speed, and wet massing time are set to distribute the API without creating localized overwetting. The binder solution is added through a nozzle; the granulation end point is detected by power-consumption or torque measurement, not by fixed time alone. Over-wetting produces coarse agglomerates and increases the drying load in the fluid-bed dryer, while under-wetting reduces granule strength and can cause segregation during tableting. The wet granules are dried to a moisture endpoint confirmed by Karl Fischer titration per Ph. Eur. 2.5.12; the residue is then milled through a conical mill fitted with a defined screen aperture.
After drying and milling, the granulate is blended with intragranular and extragranular disintegrant and lubricated with magnesium stearate at a concentration determined experimentally. Excessive lubrication can retard disintegration and dissolution; therefore the lubrication time and blender speed are controlled. The compression blend is released to a rotary tablet press after bulk density, tap density, and potency testing. Tablet hardness, thickness, and friability are adjusted to the product specification; friability is tested per Ph. Eur. 2.9.7 or USP <1216>, disintegration per Ph. Eur. 2.9.1 or USP <701>, and dissolution per USP <711> or Ph. Eur. 2.9.3.
Direct compression of low-dose spiramycin base tablets uses the micronized grade to reduce risk of content non-uniformity. The API is first dispersed by geometric dilution with a directly compressible filler such as spray-dried lactose or mannitol. The pre-blend is passed through a screen to break API agglomerates before final tumbling. Blend uniformity is assessed by sampling from multiple zones of the diffusion mixer; acceptance is based on mean potency and coefficient of variation. If the coefficient of variation exceeds the limit at scale-up, the mixing time, mixer fill volume, or pre-blend ratio is adjusted. Published data for this specific configuration is limited, so the target D10, D50, and D90 are established by the formulation scientist and controlled by the API supplier’s certificate of analysis.
Capsule filling of spiramycin base is performed on tamping-pin or dosator-type capsule fillers. Tapped density per Ph. Eur. 2.9.34 and compressibility index are used to anticipate flow behavior; a high compressibility index indicates poor flow and may require precompaction or the addition of a glidant. Fill weight is controlled by periodic weight checks, and powder bed height is maintained within a defined range. The formulation may be dry-filled to avoid exposing the API to moisture; if wet granulation is necessary, the granules are dried to the moisture limit before encapsulation.
Granules for oral suspension or pediatric sachets require taste-masking because the base is bitter. Spiramycin base granules are coated in a Wurster bottom-spray fluid-bed unit with an ethylcellulose or methacrylate copolymer dispersion. The spray rate, atomizing pressure, and inlet air temperature are adjusted to prevent agglomeration and moisture accumulation. The coating endpoint is determined by the target weight gain; incomplete coating exposes the bitter API and reduces patient acceptability. The coated granules are sieved and blended with a suspending agent, buffer, and sweetener before packaging in moisture-protective laminate sachets. The final sachet is tested for reconstitution time, sedimentation behavior, and microbiological quality according to Ph. Eur. 2.6.12 and 2.6.13.
The designation “Pharma Grade” requires manufacture under current GMP for active substances per ICH Q7 and EU GMP Part II. The supplier maintains a valid drug master file or CEP where applicable, and each batch is released against a certificate of analysis that includes the specification, test method, and numerical result. For oral solid and injectable applications, the applicant must verify that the selected grade meets the respective monograph or regulatory dossier; the API alone does not define the finished-product safety or efficacy.
A formulator cannot interchange spiramycin base with spiramycin adipate or acetylspiramycin on an equal-weight basis. The base is a free base complex requiring salt or solvent assistance for rapid aqueous dissolution, while the adipate salt provides improved water solubility and is commonly used in parenteral solutions. Acetylspiramycin is a derivative with different physicochemical and pharmacokinetic properties. Dosage conversion from base to salt or derivative must be calculated from the assigned potency in IU/mg and the molecular mass difference; assay methods must be specific for the intended form to avoid overestimating active content.
The base is a multicomponent complex; the ratio of spiramycin I, spiramycin II, and spiramycin III is not fixed by the empirical formula alone. Fermentation conditions, extraction solvent, and crystallization solvent influence the component ratio. A certificate of analysis that reports only a single total potency may not describe the component profile; the HPLC fingerprint is therefore a critical release and stability parameter. Compared with a chemically synthesized single-entity macrolide, spiramycin base has a broader impurity matrix and requires stricter control of residual solvents and elemental impurities because fermentation-derived materials are exposed to multiple solvents and filtration aids.
Spiramycin adipate is prepared from the base by salt formation with adipic acid. The salt form is selected for parenteral solutions because it dissolves in water more readily than the free base. However, the salt content shifts the mass balance: the same mass of adipate contains less active macrolide than the base. Manufacturers therefore state potency in international units per milligram for both materials, and the conversion between base and salt is made using the assigned potency factor. Acetylspiramycin is an acetylated derivative; it is not equivalent to the base in terms of chromatographic retention time, solubility, or dosing. A compendial method suitable for spiramycin base may not resolve acetylspiramycin without adjustment; method validation must include specificity for the intended derivative.
| Attribute | Spiramycin base | Spiramycin adipate | Acetylspiramycin |
|---|---|---|---|
| Chemical nature | Free base complex of spiramycin I, II, III | Salt of spiramycin and adipic acid | Acetylated derivative of spiramycin |
| Water solubility | Practically insoluble | Soluble | Low aqueous solubility relative to salt |
| Primary dosage form | Tablet, capsule, granule, sterile suspension | Injectable solution, some oral forms | Oral solid or suspension |
| Potency expression | IU/mg on dried basis | IU/mg with salt factor | Potency by compendial assay |
| Compendial identity | HPLC component ratio per Ph. Eur. 2.2.29 | HPLC and salt identification per monograph | HPLC derivative profile per monograph |
| Manufacturing route | Fermentation and purification | Salt formation from base | Acetylation of base |
When spiramycin base is specified for an injectable product, the formulation pathway is more constrained than for a soluble spiramycin salt. The base is practically insoluble in water; therefore, a ready-to-use aqueous solution cannot be prepared by simple dissolution unless a co-solvent or complexing agent is used and the safety and sterility of the final formulation are demonstrated. More commonly, the injectable-grade base is used in a sterile suspension for intramuscular administration or as a starting material for aseptic conversion to a soluble salt in a closed process. The sterile-micronized API is characterized by particle-size distribution, crystallinity, and bulk powder sterility; the final suspension is tested for particulate matter per Ph. Eur. 2.9.19, sterility per Ph. Eur. 2.6.1, and bacterial endotoxins per Ph. Eur. 2.6.14.
The injectable-grade base differs from the oral grade in bioburden control. The powder is sterile and has a controlled bacterial endotoxin limit. However, the free base is not a solution-forming API at neutral pH; if the marketed injection is a solution, the manufacturer generally converts the base to a salt under controlled conditions before formulation. If the marketed injection is a suspension, the base is micronized aseptically and dispersed in a vehicle containing a wetting agent and a suspending agent. The rheology of the suspension is measured with a rotational viscometer; the yield stress must be sufficient to prevent sedimentation, but low enough to permit syringeability through a designated needle gauge. The particle-size distribution of the sterile micronized API is measured before compounding, and the final suspension is monitored for particle aggregation during stability studies.
Terminal sterilization of a spiramycin base suspension is limited by the thermal sensitivity of the macrolide ring. Steam sterilization at 121 °C for 15 min is not applied unless the formulation is shown to maintain potency and related substances within specification after the cycle. Published data for this specific configuration is limited; therefore aseptic processing is the default route. Aseptic filling lines for sterile powders or suspensions require unidirectional airflow, qualified isolators or restricted-access barrier systems, and validated sterilizing-grade filters for the vehicle. The API is sterilized either by dry heat under conditions that do not degrade the molecule, by gamma irradiation if stability data support it, or by sterile crystallization followed by aseptic micronization. The selected method must be described in the active substance master file and supported by sterility assurance data and media-fill simulations.
Because spiramycin base is a fermentation product, the bacterial endotoxin load of the bulk powder can vary between commercial fermentation batches. Endotoxin removal occurs mainly during downstream purification, not during final dry powder blending. Injectable-grade suppliers therefore include endotoxin reduction steps such as water-for-injection rinses, ultrafiltration, or solvent precipitation. The API release limit for endotoxin is calculated from the intended maximum daily parenteral dose and the parenteral limit in the finished product; the API limit is set tighter than the finished-product limit to account for excipients, water, and packaging. The pharmacopoeial method is kinetic chromogenic or gel-clot per Ph. Eur. 2.6.14; method suitability is demonstrated by recovery experiments in the presence of the API matrix.
Finished-product development must also account for the component ratio of spiramycin I, II, and III, because the chromatographic fingerprint can shift slightly between fermentation batches. The release specification includes individual and total related substances; the stability program follows ICH Q1A(R2), and photostability is evaluated according to ICH Q1B when the route of administration includes parenteral exposure. Contact with strong oxidizing agents should be avoided, and storage is required in tightly closed containers protected from light. If aseptic transfer from the API container to the filling line is performed in a closed system, the container closure integrity and sterility assurance of the transfer path must be validated before routine production.
